Short Interest in Novozymes A/S (OTCMKTS:NVZMY) Grows By 1,727.7%

Novozymes A/S (OTCMKTS:NVZMY) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 34,196 shares, an increase of 1,727.7% from the August 15th total of 1,871 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 46,883 shares, the days-to-cover ratio is presently 0.7 days.

Novozymes A/S Price Performance

Shares of NVZMY stock opened at $65.89 on Friday. The stock has a 50 day moving average price of $66.31 and a 200 day moving average price of $61.48. Novozymes A/S has a 52-week low of $49.90 and a 52-week high of $75.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The firm has a market capitalization of $27.31 billion, a P/E ratio of 41.70, a P/E/G ratio of 2.96 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.16). Novozymes A/S had a net margin of 14.70% and a return on equity of 6.60%. The business had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.27 billion. As a group, sell-side analysts predict that Novozymes A/S will post 2.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Institutional Investors Weigh In On Novozymes A/S

An institutional investor recently raised its position in Novozymes A/S stock. Elefante Mark B lifted its stake in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.